Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Breast cancer

Recruiting

Registered drug

Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Bi 690517

Contact Research Centre

Breast cancer

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Breast cancer+1

Recruiting

Investigational

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Sargramostim

Contact Research Centre

Breast cancer+4

Recruiting

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Elacestrant

Contact Research Centre

Breast cancer metastatic

Recruiting

Registered drug

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Letrozole

Contact Research Centre

Breast cancer metastatic

Recruiting

Registered drugNo placebo

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Breast cancer+3

Recruiting

Registered drugNo placebo

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Registered drugNo placebo

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Cardiac failure

Recruiting

Registered drug

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Bi 690517

Contact Research Centre

Malignant peritoneal neoplasm+2

Recruiting

Registered drugNo placebo

Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Registered drug

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Elacestrant

Contact Research Centre

Find therapies in clinical trials near you

30 trials match your criteria

Breast cancer

Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

Cardiovascular disorder+2

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Breast cancer

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Breast cancer+1

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Breast cancer+4

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Breast cancer metastatic

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Breast cancer metastatic

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Breast cancer+3

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Hormone receptor positive HER2 negative breast cancer

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Cardiac failure

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Malignant peritoneal neoplasm+2

Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Hormone receptor positive HER2 negative breast cancer

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.